Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
January 15, 2004Brain

Neutralizing antibodies against IFN- in multiple sclerosis: antagonization of IFN- mediated suppression of MMPs

View Full Paper
Ask AI
Bookmark
Share

Why the study?

Do neutralizing antibodies against IFN-beta reverse the suppressive effects of IFN-beta on MMP expression in patients with relapsing-remitting multiple sclerosis?

Population

Clinically stable multiple sclerosis patients with relapsing remitting disease course

Comparison

Short-term and long-term treatment with IFN-beta vs Patients without neutralizing antibodies (NAb-)

Design

Cohort

Authors

FGFrancesca Gilli

Discussion

Loading...

Member takes

Overview

NAb positivity may blunt IFN-beta efficacy via MMP changes in RRMS; supports mechanistic role but leaves open outcome impact.

Structured PICO

Do neutralizing antibodies against IFN-beta reverse the suppressive effects of IFN-beta on MMP expression in patients with relapsing-remitting multiple sclerosis?

P
Population
Clinically stable multiple sclerosis patients with relapsing remitting disease course
I
Intervention
Short-term and long-term treatment with IFN-beta
C
Comparator
Patients without neutralizing antibodies (NAb-)
O
Outcome
Expression levels of MMP-2, MMP-9, TIMP-1, TIMP-2, and MxA in peripheral mononuclear cellssurrogate

Neutralizing antibodies against IFN-beta in multiple sclerosis patients reverse the drug's beneficial suppression of matrix metalloproteinases, supporting their role in reducing therapeutic efficacy.

Cite This Study

Francesca Gilli (2004) studied this question.

synapsesocial.com/papers/6a8ce0579cd95633742f049fhttps://doi.org/10.1093/brain/awh028
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Reversal of experimental autoimmune encephalomyelitis with a hydroxamate inhibitor of matrix metalloproteases.1994 · 341 citations
  2. 2Dose Effects of Growth Hormone during Puberty2003 · 53 citations
  3. 3Matrix metalloproteinases and their tissue inhibitors as markers of disease subtype and response to interferon‐β therapy in relapsing and secondary‐progressive multiple sclerosis patients2001 · 125 citations
  4. 4Neutralizing antibodies during treatment of secondary progressive MS with interferon β-1b2003 · 82 citations
  5. 5Serum MMP-9 and TIMP-1 levels are related to MRI activity in relapsing multiple sclerosis1999 · 234 citations